The path to digitalising production processes requires not only a systematically designed approach but also a clearly calculable assurance of success in order to avoid investment risks. OYTEC has developed the “Efficiency Booster” roadmap specifically for this purpose.

Our starting point is that a company will only take the next step towards digitalisation if there are objectively assured prospects of sustainable efficiency gains. This ensures that investments pay for themselves within a few months and that the company benefits permanently from lower costs.
The “Efficiency Booster” process model is based on four steps:
- A potential calculation determines the specific cost savings that can be achieved through realistic optimisation by means of digitalisation
- Experience the benefits first-hand by introducing a quick-to-implement entry-level solution.
- Expansion of the pilot process to generate a clear and sustainable increase in efficiency based on the knowledge gained. It is also advisable to run a parallel consulting project to identify and eliminate process weaknesses.
- Flexible extension as required, through the progressive development of an integrated software environment. Simultaneous optimisation of the relevant processes is recommended.
Latest News
Fast & Furious eBR Implementation
YES, that's right, a Fast & Furious eBR Implementation is possible. It is no longer a utopia to carry out an Electronic Batch Record implementation in a fast and massive way for any manufacturing plant. Regardless of the manufacturing area: bulk, weighing, or...
EMA and FDA: The 10 Principles of Pharmaceutical AI
The European Union and the United States published the Guiding Principles for Good AI Practices in Drug Development on January 14, 2026, as part of a strategic effort to harmonize regulatory criteria. The EMA-FDA collaborative work initiative has the mission of...
The FDA and Pharmaceutical AI: Key Points from the 2025 Draft on Model Credibility
The FDA positions credibility as an indispensable condition for utilising AI in pharmaceutical regulatory decision-making, within a risk-proportionate framework that demands traceability, transparency and validation throughout the entire model lifecycle. This approach...




